外照射放疗改善低体积转移性前列腺癌患者生存:一项北美人群研究
该研究基于SEER数据库(2004-2016)分析15,494例新诊断转移性前列腺癌患者,评估外照射放疗(EBRT)对总死亡率(OM)和癌症特异性死亡率(CSM)的影响。
要点
- EBRT在M1a和M1b且PSA≤10.0 ng/ml的mPCa患者中与更低的总死亡率相关。
- M1b且PSA>10.0 ng/ml的患者未观察到EBRT的生存获益。
- 北美mPCa患者中EBRT获益人群可能比欧洲报道的更窄。
核心结论
- 在M1a和M1b且PSA≤10.0 ng/ml的mPCa患者中,EBRT与总死亡率降低相关,但在M1b且PSA>10.0 ng/ml患者中无此关联。
- 北美mPCa患者中能从EBRT获益的亚群可能比欧洲原先报道的更小。
研究设计与样本
- 基于SEER数据库(2004-2016)的人群回顾性研究,纳入新诊断M1a/b亚期且接受或未接受EBRT的mPCa患者。
- 共纳入15,494例患者,其中M1a 1,156例(7.5%),M1b 14,338例(92.5%)。
- 采用Kaplan-Meier法和Cox回归模型分析总死亡率(OM)和癌症特异性死亡率(CSM),并进行M1亚期和PSA分层分析。
- 内部验证采用2000次bootstrap重抽样。
主要发现
- 全部15,494例患者中,EBRT对OM无显著影响(HR 1.0;p=0.5)。
- M1b且PSA>10.0 ng/ml患者中未观察到EBRT与OM的显著关联。
- PSA≤10.0 ng/ml是M1b患者OM预测中最具统计学显著性的截断值。
- 以CSM为终点时,所有结果 virtually 相同。
关键数值与推荐
- PSA≤10.0 ng/ml被确定为M1b患者OM预测中最具统计学显著性的截断值。
临床怎么用
- 对于M1a或M1b且PSA≤10.0 ng/ml的mPCa患者,可考虑EBRT以改善生存。
- 对于M1b且PSA>10.0 ng/ml的mPCa患者,EBRT可能不带来生存获益,需个体化决策。
局限性
- 研究为回顾性数据库分析,可能存在选择偏倚和未测量混杂因素。
- 需要进一步的北美验证研究来确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We hypothesized that the survival benefit of external beam radiation therapy (EBRT) recorded in European low-volume metastatic prostate cancer (mPCA) patients, will apply to similar North American patients. METHODS: Newly diagnosed mPCa patients with M1a/b substages, treated with EBRT or no EBRT were abstracted from the Surveillance, Epidemiology, and End Results database (2004-2016). Kaplan-Meier plots and Cox-regression models targeted overall mortality (OM) and cancer specific-mortality (CSM) according to EBRT administration. M1 substages and PSA stratified analyses were performed. Internal validation relied on 2000 bootstrap resamples. RESULTS: Of 15,494 patients, 1156 (7.5%) were M1a vs 14,338 (92.5%) were M1b. PSA at diagnosis ≤10.0 ng/ml was recorded in 1463 (9.4%) patients. In all 15,494 patients, EBRT did not affect OM (hazard ratio [HR] 1.0; p = 0.5). However, in M1a patients and M1b patients with PSA ≤ 10.0 ng/ml EBRT was associated with lower OM (HR 0.73, CI 0.62-0.86; p < 0.001) but not in M1b patients with PSA > 10.0 ng/ml. The PSA cut-off of ≤ 10.0 ng/ml represented the most statistically significant cut-off for OM prediction in M1b patients. Moreover, internal validation with 2000 bootstrap resamples confirmed these findings. Finally, all results were virtually the same, when CSM represented the endpoint of interest. CONCLUSIONS: We validated the OM reduction associated with EBRT in M1a and M1b patients with PSA ≤ 10.0 ng/ml but not in M1b patients with PSA > 10.0 ng/ml. In consequence, it appears that a smaller subset of North American mPCa patients benefit of EBRT than originally reported in European patients. Further North American validation studies are essential.
引用
- Stolzenbach LF, Deuker M, Collà-Ruvolo C, et al. External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. Prostate Cancer Prostatic Dis. 2020. PMID: 32873918. doi:10.1038/s41391-020-00276-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。